Generex Biotechnology Announces Webcast and Invites All Shareholders to See and Listen to the Corporate Presentation from the 21st Annual H.C. Wainwright Global Healthcare Investment Conference
GlobeNewswire•September 12, 2019
President & CEO Joe Moscato and Head of Research Richard Purcell Present the “New” Generex to the Investment Community
MIRAMAR, Fla., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (GNBT) is pleased to announce that the presentation delivered by Joe Moscato, President & Chief Executive Officer and Richard Purcell, Senior Vice President of Research to the H.C. Wainwright Global Healthcare Investment Conference on Monday September 9, 2019 is now available as a webcast. Mr. Moscato and Mr. Purcell presented the Generex corporate strategy and operating plan, ongoing plans for up-listing GNBT to Nasdaq, and the exciting news about the pending acquisition of ALTuCELL and partnerships with Arizona Endocrinology Center and Paradise Valley Family Medicine to advance the treatment and management of diabetes through the NuGenerex end-to-end model for integrated disease management.
Mr. Moscato stated, “The partnerships we have established with the physician groups in Arizona under the banner of NuGenerex Health provide the platform for the future of Generex. We are re-establishing our diabetes franchise with our new model for integrated, comprehensive care with 65,000 patients, 25,000 of whom are insulin dependent. To make our model easy to understand, start with the complex, chronic patient, who accounts for the majority of healthcare costs in the U.S. With a focus on rebuilding the doctor/patient relationship we partner with specialists to provide ancillary business and clinical services through an MSO partnership with the physician groups; our MSO partners receive discount codes for NuGenerex products and services; we acquire companies like our new partner ALTuCELL to provide products and services that can be used by the physicians to take care of their patients; with the captive patient population to whom we are providing comprehensive specialty and primary care, NuGenerex Health intends to obtain to provide the end-to-end solutions under Medicare Advantage HMO contracts.”
Mr. Purcell said, “As announced on Monday, we so pleased to have the opportunity to acquire ALTuCELL, which has superior, patented microencapsulation technology for cell therapy, and which has 5 years of safety data in humans. The microcapsules will be available for licensing to biotech company partners who are seeking a solution for immune rejection and implantation safety for their cellular therapies. The value of cell encapsulation technology is well recognized, as demonstrated by the recently announced acquisition of Semma Therapeutics by Vertex, so we are very happy to have ALTuCELL as part of the NuGenerex family of companies. Additionally, ALTuCELL’s proprietary Altsulin® (microencapsulated Sertoli Cells) cellular therapy offers a potential cure for Type I diabetes; in the pre-clinical translational research in animals from rodents to primates, the microencapsulated Sertoli Cells not only activated pancreatic islet cells to secrete insulin, but also a rebalancing of the autoimmune response. We look forward to working with ALTuCELL CEO Gary Harlem and his team to become a leader in the treatment of diabetes, and we invite you to join the webcast at http://wsw.com/webcast/hcw5/gnbt/index.aspx.”